P-21 is strictly for laboratory research and is commonly employed in the following investigational areas:

Neurogenesis and Dentate Gyrus Assays

P-21 is heavily utilized in cellular models of adult neurogenesis. Researchers apply the peptide to cultured neural stem cells to quantify its ability to rapidly induce maturation and survival of newly formed neurons, mapping structural changes in the dentate gyrus.

Alzheimer’s Disease and Tau Pathology

In experimental models of neurodegeneration, researchers use P-21 to study the mitigation of tau hyperphosphorylation and the preservation of spatial memory. Assays focus on how the peptide prevents synaptic density loss and rescues cognitive endpoint markers under severe neurotoxic stress.

Traumatic Brain Injury (TBI) and Ischemia

Because of its cytoprotective traits, P-21 is investigated in mechanical trauma and stroke models. Protocols assess the reduction of secondary neuronal death and the acceleration of functional motor recovery following induced lesions to the central nervous system.

Synaptic Plasticity and BDNF Modulation

Physiological studies employ P-21 to observe its regulatory effects on native neurotrophin levels. Researchers evaluate its capacity to upregulate endogenous Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), mapping downstream enhancements in long-term potentiation (LTP).

Pathway / Mechanistic Context

The primary mechanism of action for P-21 in research settings involves the targeted antagonism of astrogliogenic pathways and the direct stimulation of neurotrophic cascades.

• LIF Pathway Modulation: P-21 competitively binds to the Leukemia Inhibitory Factor (LIF) receptor complex or directly inhibits downstream LIF signaling. Because LIF normally promotes the differentiation of neural stem cells into astrocytes (astrogliogenesis), inhibiting this pathway shifts the cellular balance entirely toward neurogenesis.
• Neurotrophin Upregulation: By acting as a CNTF mimetic, P-21 triggers the transcription of endogenous neurotrophic factors, including BDNF and NT-3. This creates a highly favorable microenvironment for synaptic repair and axonal sprouting.
• Tau and Amyloid Buffering: Increased BDNF expression driven by P-21 signaling leads to the downstream inhibition of glycogen synthase kinase-3 beta (GSK-3β), the primary kinase responsible for the pathological hyperphosphorylation of tau proteins in neurodegenerative models.

Preclinical Research Summary

Published preclinical literature documents investigations of P-21 (P021) across multiple experimental models for pathway characterization and endpoint measurement:

• Cognitive Restoration: In transgenic murine models of Alzheimer’s disease (such as the 3xTg-AD model), exogenous administration of P-21 successfully rescued spatial memory deficits and completely prevented cognitive decline when administered before the onset of severe pathology.
• Neurogenesis Induction: Research demonstrates that treatment with P-21 significantly increases the proliferation and survival of BrdU-positive neural progenitor cells in the subgranular zone of the hippocampus.
• Tau Pathology Mitigation: Cellular assays confirm that the peptide profoundly decreases tau hyperphosphorylation and reduces amyloid-beta plaque load by modulating the GSK-3β kinase pathway.
• Synaptic Density: In vitro models show that exposure to the peptide rapidly restores dendritic spine density and synaptophysin expression in neurons subjected to neurotoxic or ischemic stress.

Form & Analytical Testing

This material is produced via robust solid-phase chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Kazim, S. F., Blanchard, J., Dai, C. L., et al. (2014). Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2014.07.001
• Chohan, M. O., Li, B., Blanchard, J., et al. (2011). Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2010.01.011
• Baazaoui, N., & Iqbal, K. (2017). Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimer’s Research & Therapy. https://doi.org/10.1186/s13024-017-0173-0
• Li, B., Chohan, M. O., Grundke-Iqbal, I., & Iqbal, K. (2010). The neurotrophic peptide P021 enhances neurogenesis and memory without causing weight loss. Aging Cell. https://doi.org/10.1111/j.1474-9726.2010.00627.x
• Blanchard, J., Wanka, L., Tung, Y. C., et al. (2011). Rescue of synaptic failure and alleviation of learning and memory impairments in a transgenic mouse model of Alzheimer’s disease by a neurotrophic peptide. Neuroscience. https://doi.org/10.1016/j.neuroscience.2011.08.024

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.